Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Hamina Patel"'
Autor:
Nina Louise Jebsen, Torunn Oveland Apelseth, Hans Kristian Haugland, Øystein Rekdal, Hamina Patel, Bjørn Tore Gjertsen, Dag Eirik Jøssang
Publikováno v:
Journal of Medical Case Reports, Vol 13, Iss 1, Pp 1-9 (2019)
Abstract Background Desmoid tumors are intermediary malignant, fibrous lesions occurring in various soft tissues. Surgical treatment is relentlessly challenging because of the propensity for local aggressive behavior and high risk of recurrence. Cons
Externí odkaz:
https://doaj.org/article/91d523716cd244b5bd30a460aaad9a49
Autor:
Øystein Rekdal, Baldur Sveinbjørnsson, Vibeke Sundvold, Brynjar Mauseth, Ketil André Camilio, Fabienne Hermitte, Jérôme Galon, Hamina Patel, Andrew Saunders, Berit Nicolaisen, Paal Brunsvig, Christiane Jungels, George Lazaridis, Delphine Loirat, Rebecca Kristeleit, Ahmad Awada, Dag Erik Jøssang, Nina Louise Jebsen, Jean-Francois Baurain, Aurélien Marabelle, James Spicer
Purpose:LTX-315 is a first-in-class, 9-mer membranolytic peptide that has shown potent immunomodulatory properties in preclinical models. We conducted a phase I dose-escalating study of intratumoral LTX-315 administration in patients with advanced so
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3790033c725452f4275ac09597a9c43c
https://doi.org/10.1158/1078-0432.c.6530232.v1
https://doi.org/10.1158/1078-0432.c.6530232.v1
Autor:
Øystein Rekdal, Baldur Sveinbjørnsson, Vibeke Sundvold, Brynjar Mauseth, Ketil André Camilio, Fabienne Hermitte, Jérôme Galon, Hamina Patel, Andrew Saunders, Berit Nicolaisen, Paal Brunsvig, Christiane Jungels, George Lazaridis, Delphine Loirat, Rebecca Kristeleit, Ahmad Awada, Dag Erik Jøssang, Nina Louise Jebsen, Jean-Francois Baurain, Aurélien Marabelle, James Spicer
Table S1 shows dosing schedule and drug-related treatment-emergent adverse events occurring in at least 10% of patients in this study.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::09f01fc22e196ee509e6475cf7a8d352
https://doi.org/10.1158/1078-0432.22479504.v1
https://doi.org/10.1158/1078-0432.22479504.v1
Autor:
Øystein Rekdal, Baldur Sveinbjørnsson, Vibeke Sundvold, Brynjar Mauseth, Ketil André Camilio, Fabienne Hermitte, Jérôme Galon, Hamina Patel, Andrew Saunders, Berit Nicolaisen, Paal Brunsvig, Christiane Jungels, George Lazaridis, Delphine Loirat, Rebecca Kristeleit, Ahmad Awada, Dag Erik Jøssang, Nina Louise Jebsen, Jean-Francois Baurain, Aurélien Marabelle, James Spicer
Figure S1 shows analysis of the abundance of unique T-cell clones in blood at baseline compared to after treatment.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db0213f6daa1f3c507b9e4ebbea51215
https://doi.org/10.1158/1078-0432.22479507
https://doi.org/10.1158/1078-0432.22479507
Autor:
Nina L. Jebsen, Brynjar Mauseth, Ketil André Camilio, Ahmad Awada, George Lazaridis, Christiane Jungels, Hamina Patel, Aurélien Marabelle, Vibeke Sundvold, Fabienne Hermitte, Delphine Loirat, James Spicer, Øystein Rekdal, Berit Nicolaisen, R Kristeleit, Paal Brunsvig, Andrew Saunders, Dag Erik Jøssang, Jérôme Galon, Baldur Sveinbjørnsson, Jean Francois Baurain
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. xx, no.xx, p. xx (2021)
Purpose: LTX-315 is a first-in-class, 9-mer membranolytic peptide that has shown potent immunomodulatory properties in preclinical models. We conducted a phase I dose-escalating study of intratumoral LTX-315 administration in patients with advanced s
Autor:
Nina L. Jebsen, Torunn Oveland Apelseth, Bjørn Tore Gjertsen, Hamina Patel, Dag Eirik Jøssang, Hans Kristian Haugland, Øystein Rekdal
Publikováno v:
Journal of Medical Case Reports
Journal of Medical Case Reports, Vol 13, Iss 1, Pp 1-9 (2019)
Journal of Medical Case Reports, Vol 13, Iss 1, Pp 1-9 (2019)
Source at https://doi.org/10.1186/s13256-019-2088-6. Background - Desmoid tumors are intermediary malignant, fibrous lesions occurring in various soft tissues. Surgical treatment is relentlessly challenging because of the propensity for local aggress
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da057b2d9a5c4dcb3a30a5c3b43e4607
https://hdl.handle.net/10037/16430
https://hdl.handle.net/10037/16430
Autor:
James Spicer, Paal Brunsvig, Baldur Sveinbjørnsson, Hamina Patel, Rebbecca S. Kristeleit, Dag Erik Jøssang, Delphine Loirat, Jérôme Galon, Jean-François Baurain, Nina L. Jebsen, Ahmad Awada, Vibeke Sundvold Gjerstad, Aurélien Marabelle, Øystein Rekdal, Fabienne Hermitte
Publikováno v:
Cancer Research. 79:CT010-CT010
Background: LTX-315 is a first-in class oncolytic peptide that has the ability to kill cancer cells and induce specific anticancer immune response when injected locally into experimental tumors in mice. The underlying mechanism of action includes ind
Autor:
Aurelien Marabelle, Jean-Francois Baurain, Ahmad Awada, Rebbecca S. Kristeleit, Delphine Loirat, Dag E. Jossang, Nina L. Jebsen, Baldur Sveinbjornsson, Øystein Rekdal, Vibeke S. Gjerstad, Paal Brunsvig, Jerome Galon, Fabienne Hermitte, Hamina Patel, James Spicer
Publikováno v:
Cancer Research. 79:CT069-CT069
Background: LTX-315 is a first-in class oncolytic peptide that has the ability to kill cancer cells and induce specific anticancer immune response when injected locally into experimental tumors in mice. The underlying mechanism of action includes ind
Autor:
Simon Rule, Jan Walewski, Ofer Shpilberg, Suzette Girgis, Huaibao Feng, Hamina Patel, Vernon J. Louw, Andrzej Hellmann, Donna Skee, Helgi van de Velde
Publikováno v:
Clinical pharmacokinetics. 50(12)
Bortezomib, an antineoplastic agent with proteasome inhibitory activity, is extensively metabolized by the hepatic microsomal cytochrome P450 (CYP) enzymes CYP3A4 and CYP2C19. Drugs that affect these enzymes may therefore have an impact on the pharma
Autor:
Ofer Shpilberg, Jan Walewski, Donna Skee, Hamina Patel, Vernon J. Louw, Suzette Girgis, Helgi van de Velde, Simon Rule, Andrzej Hellmann, Huaibao Feng
Publikováno v:
Blood. 116:3983-3983
Abstract 3983 Background: Bortezomib is primarily metabolized by cytochrome P450 (CYP) 3A4 and 2C19 enzymes. Effects of co-administration of rifampicin (a potent CYP3A4 inducer) and dexamethasone (weak CYP3A4 inducer) on the pharmacokinetic (PK), pha